TNFSF11 and Fabry disease: (b) Systematic collection of pre- and post-treatment bone specimens as part of a prospective clinical trial provided a unique opportunity for detailed histopathological and molecular characterization of human tissue, a critical step in defining the role of RANKL and its inhibition in FD pathogenesis and treatment.